Drugs / ChAdV63.HIVconsv
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02362217 | Oct 2014 → Aug 2016 | HIV infectious disease, hepatitis C virus infection | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01712425 | Oct 2012 → Oct 2015 | HIV infectious disease | IrsiCaixa | Completed | No outcome recorded |
| Phase 1 | NCT01151319 | Oct 2010 → Apr 2014 | HIV infectious disease | University of Oxford | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02425241 | Oct 2013 → Feb 2016 | HIV infectious disease | University College, London | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02336074 | Nov 2015 → Nov 2017 | HIV infectious disease | Imperial College London | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdV63.HIVconsv | “ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines” NCT01712425 ↗ |
| Known as | ChAd | “ChAdV63.HIVconsv (ChAd) prime and MVA.HIVconsv (MVA) boost vaccines” NCT02336074 ↗ |
| Modality | Vaccine | “A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and...” NCT01151319 ↗ |
| Route | Intramuscular | “delivered intramuscularly” NCT01712425 ↗ |